CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

siponimod

Last Updated: May 11, 2020
Result type: Reports
Project Number: SR0631-000
Product Line: Common Drug Review

Generic Name: siponimod

Brand Name: Mayzent

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Secondary progressive multiple sclerosis

Manufacturer Requested Reimbursement Criteria1: For the treatment of patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability.

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedAugust 28, 2019
Patient group input closedOctober 18, 2019
Clarification:

- Patient input submission received from the Multiple Sclerosis Society of Canada

Patient input summary sent for review to patient input groupsOctober 28, 2019
Patient group comments on input summary closedNovember 04, 2019
Clarification:

- Patient input summary feedback received

Submission receivedSeptember 26, 2019
Submission acceptedOctober 10, 2019
Review initiatedOctober 11, 2019
Draft CADTH review report(s) sent to sponsorApril 30, 2020
Comments from sponsor on draft CADTH review report(s) receivedMay 11, 2020
CADTH review team's comments on draft CADTH review report(s) sent to sponsorJune 05, 2020
Canadian Drug Expert Committee (CDEC) meetingJune 17, 2020
CDEC recommendation sent to sponsor and drug plansJune 29, 2020
To
July 02, 2020